The Latest

NOW AVAILABLE: For the U.S. Narcotic Analgesics Market – A SnapShot analysis of HCP targeted promotional messaging and DTC initiatives for Q1 2017.

The majority of marketing materials continued to highlight the products’ abuse deterrent formulations, which discourage abuse as well as pharmacy theft. Pfizer released core materials promoting its brand Embeda as “the first and only ER morphine with sequestered naltrexone HCL,” which acts as an antagonist if the opioid is tampered with. Egalet Inc. noted that its product, Oxaydo, is the “first and only formulation of immediate-release oxycodone that discourages abuse via snorting.” Additionally, with the FDA approval of Arymo ER, Egalet announced the product’s co-pay card, which allows commercially insured patients to pay $0 for their first prescription. Additional insights into marketing strategies and channel utilization are available in the full Q1 report.

narc-2017

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, our online database of virtually all digital and print promotion distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact: US Markets: Christine Alongi at Alongi@dtwresearch.com \\ Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

NOW AVAILABLE: For the Antidepressants Market – A SnapShot analysis of HCP targeted promotional messaging and DTC initiatives for Q1 2017.

When taking a look at distributional volume between all brands, the majority of marketing materials were received for Pfizer’s Pristiq, comprising 21% of the 81 new pieces received this quarter. Pristiq emphasized formulary coverage, patient savings, and patient support in a number of physician-directed pieces. Otsuka continued to feature the “Make Way” campaign for Rexulti, with a tagline suggesting the brand offers “an option that may provide a combination of efficacy and safety to help reach treatment goals.” A new variation of AstraZeneca’s Seroquel XR “I’m OK” campaign encouraged healthcare professionals to stay together and “open up to the possibilities.” Takeda and Lundbeck continued to display the “Tangled” campaign to support Trintellix, which highlighted depression symptoms. Additional insights into marketing strategies and channel utilization are available in the full Q1 report.

Q1-2017-Antidepressants

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, our online database of virtually all digital and print promotion distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

NOW AVAILABLE: For the European NSCLC Market – A SnapShot analysis of promotional messaging and DTC initiatives for Q1, 2017.

The European NSCLC market produced 61 pieces in Q1. Overall, the main promotional topics in the European NSCLC market have been the introduction of comparative clinical studies to support efficacy and safety and the extension of indications due to the presence of mutations in NSCLC, such as Roche’s Avastin/Tarceva combination to treat NSCLC patients with EGFR mutation. The promotional leader was BI’s Opdivo (20%), which has maintained its position from last quarter. Additional insights into marketing strategies and channel utilization are available in the full Q1 report.

Q1-2017-NSCLC

About SnapShot

Helping to keep abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, the digitalized database of virtually all promotional materials distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

Tagged with:
 

NOW AVAILABLE: For the International RA Market – A SnapShot analysis of promotional messaging and DTC initiatives for Q1, 2017.

Overall, the Canadian and European RA market distributed 128 pieces during this quarter. AbbVie’s Humira and Biogen’s/Samsung’s Benepali generated the highest volume of pieces per brand, capturing 30% of the promotional volume. Amgen’s Amgevita and Solymbic along with Pfizer’s Lifmior and Sanofi’s/Regeneron’s Kevzara debuted in the international market in Q1, providing more options for RA therapy. Major brands such as Enbrel, Humira, and Simponi focused on patient and HCP support by offering services to facilitate treatment management, while highlighting efficacy with clinical studies. Biosimilars marketed comparability and quality in the treatment of RA to encourage therapy switch. Additional insights into marketing strategies and channel utilization are available in the full Q1 report.

Q1-2017-RA

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, the digitalized database of virtually all promotional materials distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

Tagged with:
 

NOW AVAILABLE: For the European Spondyloarthropathies (PsA) Market – A SnapShot analysis of promotional messaging and DTC initiatives for Q1, 2017.

The Spondyloarthropathies market for PsA distributed 120 pieces during Q1, with Novartis’s Cosentyx and Janssen’s Stelara generating most of the promotional volume per brand (14% and 15%, respectively). New therapies were introduced, such as Amgen’s biosimilar Amgevita, and comparative studies, efficacy trials, and patient support represented the most important promotional elements. In addition, Celgene’s Otezla continued with its “Billboard” campaign imagery, while Cosentyx introduced the “Generation in Motion” campaign theme. Additional insights into marketing strategies and channel utilization are available in the full Q1 report.

Q1-2017-PsA

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, the digitalized database of virtually all promotional materials distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Primary Care Markets and Specialty Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

Tagged with:
 

NOW AVAILABLE: For the International Biosimilars Market – A SnapShot analysis of promotional messaging and DTC initiatives for Q1, 2017.

Biogen’s/Samsung’s Benepali generated alone almost half of the promotional materials (44%) during this quarter. New biosimilar products, such as Pfizer’s Lifmior, were introduced, while emphasizing comparability and safety when switching from biologics to biosimilars as well as the promotion of patient support. In addition, Celltrion’s Remsima and Inflectra maintained their respective promotional campaign themes from previous quarters. Additional insights into marketing strategies and channel utilization are available in the full Q1 report.

Q1-2017-Biosimilars

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, the digitalized database of virtually all promotional materials distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

NOW AVAILABLE: For the European Spondyloarthropathies (AS & nr-axSpA) Market – A SnapShot analysis of promotional messaging and DTC initiatives for Q1, 2017.

The Spondyloarthropathies market for AS and nr-axSpA market generated 95 pieces during Q1, with Novartis’s Cosentyx and AbbVie’s Humira capturing the majority of promotional volume per brand (21% and 20%, respectively). Amgen’s Amgevita and Solymbic along with Pfizer’s Lifmior were introduced. Comparative studies between therapies were presented for biosimilars, while brands focused on patient support, with programs such as Humira’s AbbVie Care, and convenience, with Simponi’s new 100 mg dose. In addition, Novartis’s Cosentyx launched the new “Generation in Motion” campaign across Europe. Additional insights into marketing strategies and channel utilization are available in the full Q1 report.

Q1-2017-AS-and-nr-axSpA

About SnapShot

Helping to keep abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, the digitalized database of virtually all promotional materials distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

Tagged with:
 

NOW AVAILABLE: For the U.S. Chronic Idiopathic Constipation and Opioid-Induced Constipation Market – A SnapShot analysis of HCP targeted promotional messaging and DTC initiatives for Q1 2017.

Daiichi-Sankyo/Astra Zeneca’s promotion of Movantik, when evaluated on quantitative data, was cited with a substantial increase compared to Q4 2016, which allowed the product to take the lead against the market’s top competitors, Amitiza and Linzess. Bristol-Myers Squibb formulated a strong launch campaign for its newly approved CIC therapy, Trulance. Within Trulance’s quarterly analysis, the first branded materials announced its FDA approval, featured a new visual campaign, and discussed a series of access and support services for patients. Additional insights into marketing strategies and channel utilization are available in the full Q1 report.

CIC-2017

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, our online database of virtually all digital and print promotion distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact: US Markets: Christine Alongi at Alongi@dtwresearch.com \\ Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

NOW AVAILABLE: For the U.S. Antiretrovirals (HIV) Market – A SnapShot analysis of HCP targeted promotional messaging and DTC initiatives for Q1 2017.

Gilead dominated the HIV market during this time period, producing nearly half of the promotional volume received in support of its HIV franchise. HCPs were the primary targets for materials, with almost twice as many directed toward them as consumer pieces. Digital distribution took precedence as 42% more e-media pieces were noted versus print. Messaging across brands consistently promoted various savings and support programs, along with education on the products and HIV, including prevention campaigns. Clinical trial data highlighted efficacy, sometimes in comparison with other products. Campaign themes were common, often displaying similar characteristics between brands within a company. Pediatric indications were also highlighted for certain products, and Merck’s Isentress HD was announced as coming soon. Additional insights into marketing strategies and channel utilization are available in the full Q1 report.

Q1-2017-HIV

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, our online database of virtually all digital and print promotion distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

NOW AVAILABLE: For the Immunoglobulin Market – A SnapShot analysis of HCP targeted promotional messaging and DTC initiatives for Q1 2017.

Within the first quarter of 2017, DTC communications for Shire’s Cuvitru debuted a new graphic campaign to help inspire those with primary immunodeficiency to ‘Stay true to themselves’ and put up a courageous fight against the illness. This new ad featured headlines including, “Guess what, PI? Shire has my back.” and “Listen, PI. I’ll tell you who’s in charge.” Additional insights into marketing strategies and channel utilization across all PI brands are available in the full Q1 report.

immuno-Q1-2017

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, our online  database of virtually all digital and print promotion distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more. Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact: US Markets: Christine Alongi at Alongi@dtwresearch.com \\ Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com